OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept studyB E Sands, Julián Panés, Martha Marko et al.|Journal of Crohn s and Colitis|2022Cited by 33
OP23 Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative ColitisSaranya Sridhar, Patrick Branigan, Andrew Hart et al.|Journal of Crohn s and Colitis|2024Cited by 3